Posttranslational Modifications and the Immunogenicity of Biotherapeutics - Test2 - elhamkhani - TriplyDB

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

http://www.wikidata.org/entity/Q26748614

about

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.Advances in MALDI imaging mass spectrometry of proteins in cardiac tissue, including the heart valve.Semisynthetic Bioluminescent Sensor Proteins for Direct Detection of Antibodies and Small Molecules in Solution.Evaluation of heavy chain C-terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cells.Recombinant Proteins and Monoclonal Antibodies.Biologics: structural heterogeneity and immunogenicity.Inhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.

P2860

Q26738810-E337E365-D07B-4686-96D0-453424B4C71B Q33641909-1D1BFC29-0B9C-476B-B8C3-D3A7C3A3BB7B Q36322804-24ECCF95-8C85-47D7-AD59-33367C666B41 Q47108229-A2A2F76A-1706-4A42-A561-ABACB82A09A5 Q47439837-7A271088-9893-4E9B-971F-830783B2A4BF Q47602370-8ED3E33C-D23E-4DFF-B22B-FF8805396CDD Q47983376-079C2F5B-760D-49C7-B15D-B856D34414B0 Q50117760-F8077C9E-49CB-444D-91D2-2EA2BD86F52E

P2860

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

http://www.wikidata.org/entity/Q26748614

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@ast

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@en

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@nl

type

label

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@ast

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@en

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@nl

prefLabel

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@ast

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@en

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@nl

P1433

Q26748614-DEEB86C1-B0C3-4FBE-A9C1-76A32649014B

P1476

Q26748614-39AC5452-779C-4572-8961-ED2D959736D6

P2093

Q26748614-9CE9B9E6-EFB0-4868-B132-97E621E57231

P275

Q26748614-8EC9A1B5-D70E-4A72-A77D-19E9EA650EFF

P2860

Q26748614-017F4BAD-BEBC-41EB-B48A-CD1FF0DC5D59

Q26748614-01E922AE-E761-4B22-9C9D-4C9C0AD00343

Q26748614-031DD5A4-B3BB-474E-AE9D-D58737E62055

Q26748614-031E88DC-6CFC-4809-BC95-DBA670CC1362

Q26748614-0362B1D2-E2C8-40A2-8B37-5E86E281B982

Q26748614-05BD400E-8D49-4460-B2CF-4A3E041B78B4

Q26748614-05E9C676-C2CA-4FBC-BA50-031B4A51AA9F

Q26748614-06A5C900-3AC2-4AC3-9EBB-B6A7CD5A369B

Q26748614-07E3944F-B19F-46AD-A8BB-0791FB1F9E68

Q26748614-0AA5D116-BA62-4821-92C3-822B987C0C26

P304

Q26748614-6A4E365C-09D6-4E19-BA08-361F5B249C2D

P31

Q26748614-81D56320-A70E-49BC-8136-C4F2ED9529A3

Q26748614-FA13332D-A07C-4820-8B77-3646862AC8D0

P3181

Q26748614-4C90B09A-245D-4656-9CCB-A50D92EA9552

P356

Q26748614-577D19D2-39F8-4C06-9994-BCEF898E37ED

P407

Q26748614-F7DE2A5C-77B8-4E15-A979-98F758036C07

P478

Q26748614-1C5A5858-870F-47B0-B46E-579FF0B0E3F1

P577

Q26748614-9673DC4F-7CE7-4D86-A2D0-A677590B5F41

P698

Q26748614-BCC62BBD-38FD-4555-B2A6-DE103D0A4C21

P921

Q26748614-2EB19907-CA2F-411E-90DF-1FED5E1D417A

Q26748614-A53116D8-AC62-4A98-8804-3DDB9D7B90B4

Q26748614-BFB76091-5004-43B8-9531-2DF5B8AEB087

Q26748614-D684D6DD-1A7E-415A-95A6-C0C014D5CADB

Q26748614-F43DACE5-37B3-45A5-8D71-9BC87128F993

P932

Q26748614-2574C2BF-B401-4F1A-8E8D-318C8372AB0F

P3181

P356

P1433

Journal of Immunology Research

P1476

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

@en

P2093

Roy Jefferis

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding

The protein kinase complement of the human genome

The human phosphatase interactome: An intricate family portrait

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

Human immunoglobulin allotypes: possible implications for immunogenicity

Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice

Fc glycans of therapeutic antibodies as critical quality attributes

Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

P304

5358272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

418572

http://www.w3.org/2001/XMLSchema#string

P356

10.1155/2016/5358272

http://www.w3.org/2001/XMLSchema#string

P407

P478

2016

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27191002

http://www.w3.org/2001/XMLSchema#string

P921

regulation of gene expression

monoclonal antibody

recombinant protein

P932

4848426

http://www.w3.org/2001/XMLSchema#string